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a b s t r a c t
Objective: To analyze the frequency of psychiatric comorbidities in patients with systemic 
lupus erythematosus (SLE) using the systematic review method. 
Methods: A systematic literature search was performed between April and July 2011 in the 
following databases: BIREME, PubMed and CAPES thesis database. This search prioritized 
studies published over the last ten years (2001-2011), involving the presence of psychiatric 
comorbidities in patients with SLE. 
Results: Out of 314 articles published in scientifi c journals (PubMed) and 29 (BIREME), previ-
ously identifi ed ones, 13 articles on psychiatric disorders and SLE were selected so they could 
be submitted to the systematic review methodological approach. The articles indicated high 
frequency of psychiatric comorbidities, especially mood and anxiety disorders. There is no 
consensus between the disease activity and psychiatric disorders. Patients with active SLE 
showed a higher risk of developing mood disorders than patients with inactive SLE. 
Conclusion: Patients with SLE had a higher suicide risk than the general population. More 
thorough studies to evaluate the psychological and genetic role, specifi c and non-specifi c 
autoimmune infl ammatory mechanisms in mood and anxiety disorders are needed.
© 2013 Elsevier Editora Ltda. All rights reserved.
Comorbidades psiquiátricas em pacientes com lúpus eritematoso 
sistêmico: uma revisão sistemática dos últimos 10 anos
Palavras-chave:
Lúpus eritematoso sistêmico
Psiquiatria
Transtornos mentais
r e s u m o
Objetivo: Verifi car a frequência de comorbidades psiquiátricas em pacientes com lúpus eri-
tematoso sistêmico (LES), a partir do método da revisão sistemática. 
Métodos: Uma busca sistemática na literatura foi realizada no período entre abril e julho de 
2011, nos portais: BIREME, PubMed e banco de teses da CAPES. Essa busca priorizou estudos 
publicados nos últimos 10 anos (2001-2011), que envolvessem a presença de comorbidades 
psiquiátricas em pacientes com LES. 
Resultados: De 314 artigos publicados em periódicos científi cos (PubMed) e 29 artigos (BI-
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REME) previamente identifi cados e selecionados, foram selecionados 13 artigos sobre 
transtornos psiquiátricos e LES para submissão à abordagem metodológica de uma revisão 
sistemática. Os artigos indicaram alta frequência de comorbidades psiquiátricas, princi-
palmente transtornos do humor e de ansiedade. Não há um consenso entre a atividade da 
doença e os transtornos psiquiátricos. Pacientes com atividade da doença apresentaram 
um risco maior de desenvolver transtorno do humor do que pacientes com doença inativa. 
Pacientes com LES apresentaram mais risco de suicídio do que a população em geral. 
Conclusão: Estudos mais detalhados para avaliar o papel psicológico, genético, mecanismos 
autoimunes específi cos e não específi cos infl amatórios nos transtornos do humor e de an-
siedade são necessários.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Systemic lupus erythematosus (SLE) is a chronic infl amma-
tory and autoimmune disease of multifactorial etiology that 
can affect many organs and systems.1 The studies show a 
higher prevalence in women (approximately 90% of cases), 
especially during childbearing years, i.e. between 15 and 45 
years of age; more common in women of black ethnicity than 
in Caucasian ones at a ratio of 3:1 , but it can occur in all eth-
nic groups and geographic regions.2
The central nervous system is often affected by this dis-
ease, causing neurological and/or psychiatric symptoms.1-3 
The prevalence of neuropsychiatric disorders in SLE reported 
in the literature is variable (14-75%), refl ecting the variation 
in diagnostic criteria and selection of the study population, 
which can manifest at any time during the course of the dis-
ease with different clinical forms, from mild to severe ones.4 
Psychological stress is considered by many academics as be-
ing of particular importance in triggering the disease and its 
exacerbations.5-7 Psychiatric syndromes in patients with SLE 
include a variety of psychiatric fi ndings causing chronic dis-
abilities.8
The American College of Rheumatology (ACR) classifi ed 19 
neuropsychiatric syndromes related to SLE, describing them 
as psychiatric manifestations, psychosis, mood disorders, 
anxiety disorders and acute confusional state.1 
Thus, during the clinical treatment of patients, in addition 
to the need to consider the disease itself, it would be appro-
priate to observe the specifi c psychiatric manifestations and 
determine how these comorbidities result in daily life activity 
limitations, affecting the quality of life of the individual.9
The aim of this review is to assess the frequency of psychi-
atric comorbidities in patients with SLE.
Material and methods
A systematic literature search was performed between 
April and July of 2011 at the following databases: BIREME, 
PubMed and CAPES thesis database. This search prioritized 
studies published in the last 10 years (2001-2011) that in-
cluded the presence of psychiatric comorbidities in pa-
tients with SLE.
The aim of this study was to collect and synthesize re-
search results systematically. For this purpose, our guiding 
question was: What is the frequency of psychiatric comor-
bidities in patients with SLE? Thus, the expected primary 
outcome is that psychiatric comorbidities are frequent and 
identifi ed at some level of SLE activity. As secondary out-
come, it is likely that among the observed comorbidities, 
depression is the most frequent among SLE patients. 
Aiming to clearly defi ne the pertinence of the literature 
found for this review study, the following inclusion crite-
ria were established: a) articles with human subjects; b) 
articles published in the last 10 years; c) patients of both 
genders; d ) aged 19 years and older; e) articles published in 
English, Portuguese and Spanish; and f) prospective stud-
ies.
The exclusion criteria were developed to eliminate ar-
ticles that did not follow these parameters in their meth-
odology: a) review studies; b) short communications; c) 
qualitative studies; d) publications in other languages , even 
when they had an abstract in English; e) intervention stud-
ies; f) and case reports.
The search was performed by three researchers. Two re-
searchers (NMJA and MGWS) were responsible initially for 
independent and blind searches. A third investigator (OGL), 
the reviewer, was consulted in cases of disagreement to es-
tablish a consensus. The data collection forms were stan-
dardized and created before the search was started. 
The key words were chosen according to the DeCS/ 
MeSH list. The DeCS list had the following key words: Sys-
temic Lupus Erythematosus and Psychiatry. The MeSH list 
had the following ones: Lupus Erythematosus, Systemic 
and Psychiatry (Table 1). The references from selected ar-
ticles were also reviewed to identify other relevant studies 
that might have been omitted during the electronic search.
The search was carried out in more than one site and 
several databases including thesis and dissertation data-
bases. The search strategy followed the recommendations 
by Castro et al.,10 Dickersin et al.11 and the Cochrane Col-
laboration.
All articles obtained in the search were organized in 
tables and evaluated regarding the condition of being in-
cluded or excluded based on the eligibility criteria. The 
Jadad Scale12 was applied to evaluate the included articles, 
in which each positive response generates 1 point on the 
scale, resulting in a score of 0-5 points:
1 a. Was the study described as randomized?
1 b. Was the method adequate?
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2 a. Was the study described as double-blind?
2 b. Was the method adequate?
3. Was there a description of losses and exclusions?
Results
After the fi rst search, using the expression from item 3 (Ta-
ble 1) and without using the inclusion criteria, a total of 
1,504 articles were identifi ed in the PubMed site and 5,179 
articles in the BIREME site.
Of the 1,504 items in the PubMed site, 266 articles were 
immediately eliminated as they were review articles, of 
which 1,238 remained to be assessed. After a more care-
ful analysis following the inclusion criteria, of the 1,238 ar-
ticles, 314 were selected. 
Of the 314 articles analyzed at PubMed, 290 were exclud-
ed for the following reasons: a) case reports (18); b) neuro-
imaging study (33); c) autoantibody research (26); d) quali-
tative study (32); e) experimental study (13); f) evaluation of 
drug treatment (32); g) study with children and adolescents 
(7); h) analysis of cognitive defi cits (32); i) studies with other 
autoimmune diseases (97). A total of 11 articles remained in 
the systematic review.
In the BIREME database, of the 5.179 articles that were 
identifi ed, 29 were selected, of which four were identical to 
those found in PubMed database; thus, of the 25 remaining 
articles, only one was included in this review, for meeting 
the inclusion criteria. 
Two theses were found in the CAPES thesis database, but 
only one was selected; however, it was not possible to ob-
tain its full text. The other thesis was excluded after read-
ing its title.
The references of the 11 articles (PubMed) and one ar-
ticle (BIREME) included were analyzed and only one arti-
cle met the inclusion criteria, and thus it was selected.  
Therefore, the study of this systematic analysis included 13 
articles (Fig. 1).
In this systematic review, 11 articles achieved the high-
est score 5 on the Jadad scale.12 The number of subjects var-
ied from 46-1,206. The age studied had a wide range (16-83 
years). Mean age ranged from 32-48 years. The vast majority 
of subjects in the different studies (87-100%) were females 
(Table 2). Only three studies evaluated the age of diagnosis, 
which was around 30 years. Disease duration ranged from a 
few months in the study by Hanly et al.24 to 47 years in the 
study by Bachen et al.22 The mean duration of the disease 
ranged around nine years. 
Most articles used the SLEDAI25 tool to evaluate disease 
activity, whereas many tools were indicated for psychiatric 
evaluation, considering the terms of the DSM-IV.26
The most frequent psychiatric comorbidities were mood 
disorders and anxiety disorders. Major depressive episode 
(MDE) was the most frequent mood disorder, ranging from 
18.3-75%, whereas anxiety disorder not otherwise specifi ed 
(AD-NOS) was the most frequent among the anxiety disor-
ders, ranging from 3.6-74.6%.
Subsequently, the most commonly found anxiety Dis-
orders were: generalized anxiety disorder (GAD) 9.9%,21 
4.3%22 and 2.4%,8 obsessive-compulsive disorder (OCD) 
8.9%,22 42%19 and 3.6%,8 social phobias and specific phobia 
(SCP and SP) 12.7% and 25.4%,21  15.6% and 23.9% 22 and 
1.2% and 1.2%.8
Among other psychiatric comorbidities found, suicide 
risk (SR) was observed by Ishikura et al. (8.3%)14 and Jarpa et 
al. (9.6%),8 psychotic syndrome (SP) by Hanly et al. (5.0%)24 
and Jarpa et al. (1.2%),8 adaptation disorder (AD) by Nery 
et al. (8.4%)21  and Jarpa et al. (2.4%)8.  Table 3 summarizes 
the frequency of psychiatric comorbidades and evaluates 
articles according to Jadad criteria.12
Table 1 – Expressions used in the search (Mesh). 
Expressions N. of articles 
(Database)
1: lupus erythematosus, systemic 49,637 (PubMed)
2:  psychiatry OR psychiatric OR mental 
disorders OR depression OR emotional 
disorders OR anxiety disorders OR 
mood disorders
1,148,148 (PubMed)
3:  #1 AND #2 1,504 (PubMed)
Limits: human, English, Portuguese or 
Spanish, male, female, age older than 
19 years, published over the past 10 
years
314 (PubMed)
Maintained after exclusion criteria 11 (PubMed)
Added after reference consultation 1 (PubMed)
Added after consultation 1 (BIREME)
Included in this review 13
Fig. 1 – Study search and selection for the systematic 
review according to Cochrane Collaboration
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Discussion
Psychiatric symptoms are commonly reported in patients 
with SLE, contributing to the physical and functional morbid-
ity. That was verifi ed in the articles analyzed in this system-
atic review.8,13-24 
Although the study design did not represent an exclusion 
criterion, only Jarpa et al.8 and Hanly et al.24 described their 
studies as being prospective. However, considering the de-
scription of the procedures in the other studies, one could say 
that the design would also be prospective, cross-sectional or 
longitudinal. 
The eligibility criteria were described in detail in all arti-
cles, providing subsidies for future studies. By applying more 
stringent inclusion criteria, thus substantially reducing the 
number of articles, allowed greater consistency, homogeneity 
and reliability of the analyzed fi ndings.
The size of the samples studied in the thirteen articles 
was widely variable, depending mainly on the study aim and 
methodology used. While Ainiala et al.13 described the preva-
lence of neuropsychiatric syndromes in a Finnish population 
represented by 46 subjects, Hanly et al.24 carried out a multi-
center study to determine the frequency, the monitoring of 
neuropsychiatric events and their impact on quality of life in 
the fi rst three years of the disease, obtaining a much larger 
sample of 1,206 subjects. 
The mean disease duration was similar between articles, 
lasting approximately 10 years. The samples of subjects with 
SLE were predominantly female in all articles (87-100%). 
Male subjects were analyzed in 9 articles, but no character-
istics of this group were recorded separately among the re-
sults.8,13,15-19,23,24 Some articles had in common an evaluation 
regarding the contribution of social factors, mainly those re-
lated to ethnicity in subjects with SLE.8,15,24,14,18
Jarpa et al.8 described for the fi rst time the prevalence 
of psychiatric disorders in Chilean patients of mixed blood 
(Amerindian/Spanish) with a diagnosis of SLE, observing con-
siderably higher frequencies than those seen in the general 
population and no association with disease activity. Brey et 
al.15 studied a predominantly Mexican-American population, 
comprising much of the San Antonio (Texas) region, where 
psychiatric disorders in patients with SLE were also very fre-
quent.
Ainiala et al.,13 when analyzing 46 Finnish subjects with a 
diagnosis of SLE, found that 42 patients met at least one neu-
ropsychiatric criterion established by the ACR.
The studies by Iverson16 and Hanly et al.24 observed a pre-
dominance of Caucasians among the several ethnic groups 
studied. Bachen et al.22 described the prevalence of mood and 
anxiety disorders in Caucasian women and Slattery et al.,19 an-
alyzing the prevalence of OCD in SLE patients, found that 71% 
of patients were Caucasians. 
The most widely used tool in the assessment of dis-
ease activity was SLEDAI,25 which has been used for the as-
sessment of disease activity in multiple centers with good 
results regarding its validity and reproducibility. In some 
studies this tool did not contribute to the association be-
tween the presence of psychiatric disorders and disease ac-
tivity, perhaps by the diversity of disorders present in this 
sample, including different forms of anxiety and alcohol-
ism or probably because mechanisms that are intrinsic to 
SLE may participate in the pathogenesis of each psychiatric 
disorder.8,21 On the other hand, the study by Nery et al. 20 
reported a trend of association between MDE with disease 
activity.
In this review, the studies by Iverson,16 Slattery et al.19 and 
Philip et al.23 have not applied any tool to assess disease ac-
tivity, as their objectives did not include the analysis of this 
activity.
Articles trying to defi ne the prevalence of psychiatric dis-
orders showed variations regarding patient selection, type of 
study and clinical defi nitions of psychiatric comorbidities, 
contributing to different results.8, 13-24
During the course of the disease, depression and anxi-
ety symptoms have been often observed by several au-
thors.8,17,18,21,22 In this systematic review, the most common 
psychiatric comorbidity was MDE, ranging from 18.3-75% in 
different studies.8,13,15-18,20,22,23 The negative perception of the 
disease would be associated with different levels of depres-
Table 2 – Clinical and demographic characteristics of the 13 articles of the systematic review in patients with SLE in the 
past 10 years.
Author n Age (years) Gender Age at diagnosis (years) Duration (years) DAI
Ainiala 46 45 ± 13 (20-64) 39Ƃ, 7ƃ - 14 ± 8 (2-37) ECLAN
Ishikura 84 41 ± 12 (20-68) 84Ƃ 31 ± 10 (14-60) 11 ± 7 (1-29) LACC
Brey 128 43 (21-71) 120Ƃ, 8ƃ - 8 ( 0.2-37) SLEDAI SLICC
Iverson 103 48 ± 13 102Ƃ, 1ƃ - - -
Appenzeller 40 32 37Ƃ, 3ƃ - - SLEDAI
Doria 126 39 ± 12 (18-65) 110Ƃ, 16ƃ - 10 ± 6 (1-32) ECLAN SLICC
Slattery 50 42.1 ± 11.1 (20-71) 45Ƃ, 5ƃ 26.8 ± 10.3(7-60) 15.3 ± 9.1(1-34) -
Nery 71 35 ±  10 (19-65) 71Ƃ - 10 ± 7 (0-29) SLEDAI SLICC
Nery 71 35 ± 10 (19-65) 71Ƃ - 10 ± 7 (0-29) SLEDAI SLICC
Bachen 326 48 ± 11 (18-83) 326Ƃ 33 ± 12 (1-73) 15 ± 10 (1-47) SLAC
Philip 154 52 ± 15 140Ƃ, 14ƃ - 15 ± 10 -
Hanly 1206 35 ± 13 1080Ƃ, 126ƃ - 5(4) months SLEDAI SLICC
Jarpa 83 39 (16-72) 76Ƃ, 7ƃ - 5 (0.1-40) SLEDAI-2K
DAI, disease activity index; ECLAN, European Consensus Lupus Activity Measure; LACC, Lupus Activity Criteria Count; SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics/ACR Damage Index; SLAC, Systemic Lupus 
Activity Questionnaire.
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sion in these patients. 23 Several articles have also found a 
signifi cant prevalence of depressive disorder not otherwise 
specifi ed in these patients.14,15,20,21 
Anxiety disorders have also been described as having a 
high prevalence in SLE among the several articles,8,13-15,17-19,21,22 
especially AD-NOS, Phobias, OCD and GAD. According to 
these authors, the reason why the high prevalence of anxi-
ety disorders is considered unknown, is justifi ed by the fact 
that anxiety has not been well studied in patients with SLE. 
Patients with anxiety disorder often fi nd it diffi cult to reveal 
their symptoms, thus necessitating other evaluation methods 
such as self-reporting questionnaires for the identifi cation of 
this comorbidity.22 
The OCD is a common comorbidity in patients with SLE, 
according to the articles by Jarpa et al.,8 Bachen et al.22 and 
mainly Slattery et al.19 The purpose of this latter study would 
be to identify, among psychiatric symptoms in subjects with 
SLE, which specifi c prevalence of this disorder could be higher 
than in community-based studies. Neuroimaging studies in-
dicate changes in the basal ganglia in patients with OCD.27,28 
Evidence suggests an association between these abnormali-
ties and psychiatric symptoms in this population.29
Table 3 – Frequency of psychiatric comorbidity in patients with SLE from 13 articles of the systematic review of the past 
10 years.
Author Year PAT Mood disorders Anxiety disorders Others Jadad
Ainiala 2001 BDI 39.6%
4.4% 
MDE
BD-NOS
13% AD-NOS 5
Ishikura 2001 SDS
STAI
CMI
40.5% DD-NOS 51.2% AD-NOS 8.3% SR 5
Brey 2002 SCID 28%
19%
4%
MDE
DD-NOS
BD-NOS
24% AD-NOS 5% PD-NOS 5
Iverson 2002 BCMDI
BDI
39% MDE 4
Appenzeller 2003 BPRS
HAD
BECK
75% MDE 70% AD-NOS 3
Doria 2004 HAS
HAM-D
40.5% MDE 74.6% AD-NOS 5
Slattery 2004 Y-BOCS 42% OCD 5
Nery 2007 SCID 22.5%
4.2%
MDE
DD-NOS
5
Nery 2008 SCID 22.5%
18.3%
4.2%
4.2%
MD
MDE
THCMG
DD-NOS
1.4%
12.7%
25.4%
9.9%
12.7% 
AG
SCP
SP
GAD
AD-NOS
1.4%
1.4%
8.4%
SD
AA
AD
5
Bachen 2009 CIDI 47%
6%
3.3% 
MDE
BD I
DD
1.2% 
4.3% 
8.9% 
15.6% 
23.9% 
15.6% 
AG
GAD
OCD
SCP
SP
PD
5
Philip 2009 CDS 27% MDE 5
Hanly 2010 ACR 18.2% MD-NOS 5.0% SP 5
Jarpa 2011 MINI- plus 21.7%
4.8% 
2.4% 
MDE
DD
ME
3.6% 
3.6% 
3.6% 
2.4% 
2.4% 
1.2% 
1.2%
AD-NOS
AG
OCD
GAD
PTSD
SCP
SP
11.7%
3.6%
1.2%
9.6%
6.0%
2.4%
PDD
MADD
SP
SR
BDD
AD
5
PAI, Psychiatric Assessment Tool; AA, Alcohol Abuse; AG, Agorafobia; BCMDI, British Columbia Major Depression Inventory; BDI, Beck 
Depression Inventory; CDS, Cardiac Depression Scale; CIDI, Composite International Diagnostic Interview; CMI, Cornell Medical Index; MD, 
Major Depression; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; MDE, Major Depressive Episode; ME, Maniac Episode; SP, 
Specifi c Phobia; SCP, Social Phobia; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; MADD, Mixed anxiety-depressive disorder; MINI-plus, 
Mini International Neuropsychiatric Interview; SR, Suicide Risk; SCID, Structured Clinical Interview for Psychiatric Diagnosis; SDS, Self-rating 
Depression Scale; PS, Psychotic Syndrome; STAI, State-Trait Anxiety Inventory; AD, Adaptation Disorder; GAD, Generalized Anxiety Disorder; 
AD-NOS, Anxiety Disorder-Not Otherwise Specifi ed; BD I, Bipolar Disorder I; BD-NOS, Bipolar Disorder-Not Otherwise Specifi ed; DD, Dysthymic 
Disorder; BDD, Bodily Dysmorphic Disorder; PDD, Premenstrual Dysphoric Disorder; DD-NOS, Depressive Disorder Not Otherwise Specifi ed; 
PTSD, Posttraumatic stress disorder; MD-NOS, Mood disorder not otherwise specifi ed; OCD, Obsessive-Compulsive Disorder; PD,Panic Disorder; 
PD-NOS, Psychotic Disorder Not Otherwise Specifi ed; SD, Somatoform Disorder.
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Other psychiatric comorbidities were reported as: SR, 
psychotic disorder, AD, body dysmorphic disorder.8,14,15,21,24 SR 
is not evaluated by the criteria of the ACR30 and appears to 
be neglected in this study population. Jarpa et al.8 found a 
high prevalence (9.6%) compared with the general popula-
tion. Suicidal ideation was observed in 8.3% in the study by 
Ishikura et al.14 and was correlated with troubled relation-
ships with family members, emphasizing the importance of 
family support for these patients. 
Articles in this systematic review indicated a high fre-
quency of psychiatric comorbidities in subjects with SLE, 
especially mood and anxiety disorders. 
There is no consensus yet for the correlation between 
disease activity and several mental disorders, although the 
articles showed some methodological differences, mainly 
related to the description of the study design, the character-
ization of the sample and the different evaluation tools and 
questionnaires. Patients with disease activity had a higher 
risk of developing mood disorders than patients with inac-
tive disease, regardless of the occurrence of stressful events 
or susceptibility to recurrent major depressive disorder. 
The recognition of these associations can provide a more 
appropriate treatment of these patients and may also bring 
new knowledge to the understanding of the mechanisms in-
volved in this important clinical presentation of SLE. 
In this review study previous observations of the high fre-
quency of depressive and anxiety disorders in SLE without 
concomitant neurological manifestations were evident. 
The association between SLE  and depression deserves 
special attention, especially concerning suicide risk, as it can 
be observed that SLE patients have a higher risk of suicide 
than that of the general population. In this review, the most 
often observed anxiety disorder was the anxiety disorder not 
otherwise specifi ed.
More detailed studies to assess the psychological and 
genetic role, specifi c and non-specifi c infl ammatory auto-
immune mechanisms in mood and anxiety disorders are 
needed.
Despite the technological and scientifi c advances, SLE re-
mains a threatening disease with a chronic evolution, result-
ing in intense physical, psychological and social suffering. 
Further studies are necessary, with a larger number of sub-
jects with SLE, using standardized scales and tools.
Even non-psychiatrists should be able to recognize symp-
toms suggestive of mental disorders, especially in SLE out-
patient clinics and refer these patients to specialized treat-
ment, in order to reduce suffering caused by this disease.
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